Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12 month price objectives for Amneal Pharmaceuticals' shares. Their AMRX share price forecasts range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 72.4% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

Amneal Pharmaceuticals' stock was trading at $4.79 on January 1st, 2022. Since then, AMRX stock has decreased by 33.4% and is now trading at $3.19.
View the best growth stocks for 2022 here.

Amneal Pharmaceuticals saw a drop in short interest in the month of July. As of July 31st, there was short interest totaling 3,400,000 shares, a drop of 6.6% from the July 15th total of 3,640,000 shares. Based on an average daily volume of 696,200 shares, the short-interest ratio is currently 4.9 days. Currently, 3.5% of the shares of the company are sold short.
View Amneal Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AMRX earnings forecast.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) issued its earnings results on Friday, August, 5th. The company reported $0.19 earnings per share for the quarter, hitting the consensus estimate of $0.19. The business had revenue of $559.40 million for the quarter, compared to the consensus estimate of $534.44 million. Amneal Pharmaceuticals had a net margin of 0.68% and a trailing twelve-month return on equity of 61.08%. The firm's revenue was up 4.5% compared to the same quarter last year. During the same period last year, the firm posted $0.23 earnings per share.

Amneal Pharmaceuticals issued an update on its FY 2022 earnings guidance on Friday, August, 12th. The company provided earnings per share (EPS) guidance of $0.65-$0.70 for the period, compared to the consensus EPS estimate of $0.81. The company issued revenue guidance of $2.15 billion-$2.25 billion, compared to the consensus revenue estimate of $2.17 billion.

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Amneal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.35%), Millennium Management LLC (0.30%), Victory Capital Management Inc. (0.27%), Group One Trading L.P. (0.00%), Russell Investments Group Ltd. (0.16%) and JPMorgan Chase & Co. (0.12%). Insiders that own company stock include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah, Paul M Meister, Pradeep Bhadauria and Ted C Nark.
View institutional ownership trends.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRX stock can currently be purchased for approximately $3.19.

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $968.24 million and generates $1.99 billion in revenue each year. The company earns $91.06 million in net income (profit) each year or $0.09 on an earnings per share basis.

The company employs 7,000 workers across the globe.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.